99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients
Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label SPECT/CT (single photon emission computed tomography/computed
tomography) study to investigate the diagnosis and efficacy evaluation performance of
99mTc-3PRGD2 in rheumatoid arthritis patients. A single dose of nearly 11.1 MBq/kg body
weight of 99mTc-3PRGD2 (≤20µg 3PRGD2) will be intravenously injected into the patients.
Visual and semiquantitative method will be used to assess the whole-body planar and lesions
section SPECT/CT images. Adverse events will also be observed in the patients.
Phase:
Early Phase 1
Details
Lead Sponsor:
First Affiliated Hospital of Fujian Medical University